At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
KVD900 +1 moredrug
Likely dose
KVD900 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
In Brief
A Phase 2 clinical trial evaluating KVD900 and Placebo for Hereditary Angioedema. Completed, enrolled 84 participants across 25 sites in 10 countries.
Detailed Summary
This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema
CountriesAustria, Czechia, Germany, Hungary, Italy, Netherlands, North Macedonia, Poland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
First PostedDec 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedDec 23, 2019
Enrollment StartJul 2, 2019
Primary CompletionDec 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.5 years ago
Interventions
KVD900drug
KVD900 tablet 600 mg
Placeboother
KVD900-matched Placebo Tablet